Replies to post #240317 on Biotech Values

[DewDiligence]

The first question is whether the drug in the abstract is NL-201, or a different drug.

[dewophile]

Exactly. The agonist is designed to activate whereas the antagonist suppress immunity. It’s a bit more complicated since IL-2 at lower doses can suppress immunity vs high dose IL-2 for revving up the immune system to kill cancer cells